---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-24-000089"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:57:47.506842+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolent Q2 revenue $647M (+38% YoY); net loss narrows to $6.4M; Adj. EBITDA $52M; narrows FY outlook

## Summary
- Revenue $647.1M, up 37.9% YoY from $469.1M; net loss $(6.4)M vs $(41.4)M loss in Q2 2023.
- Adjusted EBITDA $52.0M (8.0% margin) vs $47.4M (10.1% margin) in prior year.
- Narrows full-year 2024 revenue outlook and updates Adjusted EBITDA guidance; reaffirms $300M exit run rate target.
- Performance Suite average lives grew to 6,901 from 3,810 YoY; signed new oncology and specialty deals.

## SEC filing metadata
- accession: 0001628908-24-000089
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890824000089/0001628908-24-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890824000089/evh-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-24-000089
- JSON: https://secwatch.observer/filing/0001628908-24-000089.json
- Plain text: https://secwatch.observer/filing/0001628908-24-000089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.